General Information of Drug (ID: DMRVEHY)

Drug Name
LY3012212 Drug Info
Synonyms Icrucumab
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Phase 2 [1]
Bladder cancer 2C94 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMRVEHY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [3]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [4]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [5]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [6]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
X-82 DMW1NKO Age-related macular degeneration 9B75.0 Phase 2 [8]
OCV-101 DMT9QI2 Pancreatic cancer 2C10 Phase 2 [9]
OTSGC-A24 DMN0ZQ5 Colorectal cancer 2B91.Z Phase 1/2 [10]
CEP-11981 DMYDTJ6 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
EW-A-401 DM3VC6T Peripheral vascular disease BD4Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor 1 (FLT-1) TT2Q6G1 VGFR1_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862)
2 Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.
3 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
5 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
6 Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
7 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
8 National Cancer Institute Drug Dictionary (drug id 695817).
9 Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104.
10 J Clin Oncol 33, 2015 (suppl 3; abstr 65).
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
12 DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007